LumiraDx Ltd

LMDX | $0.016 -15.0% 130M

(0.0% 1d) (0.0% 1m) (-98.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-11-16
Market Cap: $ 2,629,148

Sec Filling | Patents | 2 employees

healthcare organizations continue to wrestle with avoidable costs, preventable errors, and operational inefficiency, all while aspiring to improve their consumer experience, outcomes, and bottom line. meanwhile our economies continue to be challenged by rising healthcare costs attributable to fragmented care and long term conditions, especially diabetes, heart failure, copd, and their co-morbidities. common approaches to address these challenges – rip-and-replace information systems, deploy siloed programs that hope to “manage” high-risk patients, use minimally interconnected systems to coordinate care – have proven exorbitantly expensive, unduly cumbersome, financially unsustainable, and eventually inadequate to achieve desired benefits. lumiradx offers proven solutions to directly address these challenges, and partners with its clients to help achieve better health care, social care, and financial outcomes, an improved consumer experience, and the agility to continue this transformat

add to watch list Paper trade email alert is off

Press-releases

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
Published: 2024-01-05 (Crawled : 23:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| Email alert Add to watchlist
nasdaq business

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Published: 2023-12-29 (Crawled : 21:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| Email alert Add to watchlist
care technology roche agreement platform

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
Published: 2023-10-27 (Crawled : 21:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| Email alert Add to watchlist
MEDE | News | $0.51 0% 500

n/a

| Email alert Add to watchlist
nasdaq

LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
Published: 2023-10-20 (Crawled : 23:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| Email alert Add to watchlist
lung set heart

LumiraDx Reports Second Quarter 2023 Results
Published: 2023-08-24 (Crawled : 12:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| -96.1% | O: 4.83% H: 2.33% C: -7.02%
results

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
Published: 2023-08-16 (Crawled : 20:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| -96.0% | O: 5.9% H: 0.33% C: -3.23%
conference financial results

LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Published: 2023-07-31 (Crawled : 10:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| -95.34% | O: 6.03% H: 18.13% C: -3.82%
distribution group care expansion commercial diagnostics agreement platform

LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
Published: 2023-06-30 (Crawled : 18:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| Email alert Add to watchlist
fda covid test application

LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
Published: 2023-06-20 (Crawled : 20:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M